A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region - Trial NCT06039683
Access comprehensive clinical trial information for NCT06039683 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 266 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
AstraZeneca
Timeline & Enrollment
N/A
Dec 31, 2022
Jun 30, 2024
Primary Outcome
To describe treatments and sequencing after treatment with first line Osimertinib.,To describe real world time to the next treatment or death (rwTTNTD).
Summary
A Multicountry, Multicenter, Non-interventional, Retrospective Study to determine Real-world
 treatment patterns and associated outcomes after FIRST LINE Osimertinib in patients with
 advanced and Metastatic NSCLC harboring EGFR-activating mutations in the GCC Region
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06039683
Non-Device Trial